v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses:        
Research and development $ 2,792,000 $ 1,136,000 $ 4,707,000 $ 2,445,000
General and administrative 1,312,000 1,365,000 2,943,000 2,786,000
Impairment of goodwill 2,044,000
Total operating expenses 4,104,000 2,501,000 9,694,000 5,231,000
Loss from operations (4,104,000) (2,501,000) (9,694,000) (5,231,000)
Other income (expense), net:        
Forward sales contract expense (512,000) (5,847,000)
Change in fair value of warrant liabilities 1,000
Interest income (expense), net 55,000 99,000 5,000
Gain on extinguishment of contingent liability 41,000 41,000
Other expense, net (1,000) (123,000) (1,000) (258,000)
Total other income (expense), net 95,000 (635,000) 139,000 (6,099,000)
Loss before income taxes (4,009,000) (3,136,000) (9,555,000) (11,330,000)
Benefit (provision) for income taxes (3,000) 40,000 (11,000)
Net loss (4,009,000) (3,139,000) (9,515,000) (11,341,000)
Series A preferred stock dividend (8,000) (8,000) (8,000) (8,000)
Net loss attributable to common stockholders $ (4,017,000) $ (3,147,000) $ (9,523,000) $ (11,349,000)
Net loss per common share - basic $ (3.40) $ (15.19) $ (9.63) $ (65.22)
Net loss per common share - diluted $ (3.40) $ (15.19) $ (9.63) $ (65.22)
Weighted average shares outstanding - basic 1,183 207 989 174
Weighted average shares outstanding - diluted 1,183 207 989 174